© 2022 KOMAND Consulting
Clinic Signup Consult
LevaClinic
£199 £33
TheLondonOrthopaedicClinicUK
£250 £195
SolihullHealthCheckClinic
£225 £95
ViaClinic
£365 £170
ResilienceMedicineClinics
£299 £150
MyAccessclinics
£30 £50
TheMedicalCannabisClinics
£49 £49
ZereniaClinicUK
£80 £45
PrivateGP.comLtd
£200 £100
CannabisClinicCardiff
£250 £100
Pharmacy Distributor
DispensaryGreen
LypheGroupLtd
CuraleafPharmacy
RokshawLtd
SpecialsPharma
SpecialsPharma
UNITED KINGDOM
Population:67,511,582
GDP/Capita: USD$47,334
Retail Medical Flower Price/Gram: €13 - €16
Current Med/Rec Usage (15-64yrs): 7.2% (2017 Prevalence)
Project Twenty21 Medical Cannabis Program
Listed Ailments/Symptoms
f
Sources : World population review, World Bank, KOMAND estimate, EMCDDA
1.AnxietyDisorder
2.ChronicPain
3.Epilepsy
4.MultipleSclerosis(MS)
5.PostTraumaticStressDisorder(PTSD)
6.SubstanceUseDisorder
7.Tourette’sSyndrome
Back to Europe
STATUS
• Medicalcannabisprescriptionsarelegallypermittedatdoctors’
discretion,buttheNICEguidelinesforUKprescriptionare
restrictive(guidelinesforNHSphysicians)
• TheUKMedicalCannabisRegistrywaslaunchedbySapphire
MedicalClinicsin2019tobuildupabodyofevidenceto
supporttheUK’smedicalcannabismarket
NEWS
• AUKsupplyofBedrocancannabisoilshasbeenestablished
• Acannabisresearchcenterhasbeenestablished
• MedicalregulatorsapproveCANPAINtrialtotreatpain
Status Quo & Recent News
Products
f
Conditions listed for Project Twenty21; run by drugscience.org.uk;
supported by medical companies, The Royal College of Psychiatrists, The
British Pain Society, the United Patients Alliance, patients, peers and
medical cannabis campaigners; 20,000 patients to be subsidised to gather
solid evidence aimed at encouraging NICE to recommend further medical
cannabis products on the NHS
NICE : Cannabis-based medicinal products
Listed Ailments/Symptoms
e
1.Intractablenauseaandvomiting
2.ChronicPain
3.Spasticity
4.Severetreatment-resistantepilepsy
e
These are the conditions listed on the NICE guidelines. However, lack of
doctor education and training for medical cannabis prescriptions have
constricted the growth of prescription numbers
Patient Count 2022 (est)
20,000 (>650% increase from 2021)
Patient Count (KOMAND estimate)
b
Patients
b
The Patient Count is the total population of patients that have been
prescribed medical cannabis at some point since legalisation
This estimate is based on discussions with U.K. medical cannabis market
access and cannabis clinic companies
National Guidelines & Project Twenty21
TheHomeOffice
TheHomeOfficeactsastheUKNationalCannabisAgency,issues
licencesforcultivation,manufacturing&importofmedicalcannabis
Medicines&HealthcareproductsRegulatoryAgency(MHRA)
Setsadmissiblestandardsformedicalmarketauthorisation,
includingnarcoticmedicines.Issueswholesaletradelicences
NationalinstituteforHealth&CareExcellence(NICE)
Issuesdoctorguidelinescoveringtheprescribingofcannabis-
basedmedicinalproducts(CBMPs)
Regulatory Agencies
Cannabis
Pharma
Last Updated – Oct 2022
Product
Composition
Priceper
Gram/
mL
NoidecsT17:CONightQueen(Indica)
17%THC|<1%CBD
£8/g
CellenFlosT18:C1WhiteWidow
(Sativa)
18%THC|1%CBD
£10/g
NoidecsT19:C0GorillaGlue#4(Hybrid)
19%THC|1%CBD
£8/g
NoidecsT18:C0Delahaze(Sativa)
18%THC|<1%CBD
£5/g
NoidecsT23:C0GreenGelato(Hybrid)
23%THC|<1%CBD
£8/g
KhironT18-22:C1HinduKush(Indica)
20%THC|1%CBD
£8.50/g
NoidecsT20:C0RoyalMoby(Sativa)
20%THC|<1%CBD
£8/g
NoidecsT5:C7BalancedKush(Hybrid)
5%THC|7%CBD
£8/g
KhironT1:C14GodBud(Hybrid)
1%THC|14%CBD
£8.50/g
CellenT25:C25FullSpectrumOil
(Sativa)
25mg/mlTHC|25mg/ml
CBD
£5/ml
CellenT12:C25FullSpectrumOil
(Sativa)
12.5mg/mlTHC|25mg/ml
CBD
£5/ml
CellenT10:C10FullSpectrumOil
(Sativa)
10mg/mlTHC|10mg/ml
CBD
£5/ml
KhironKhirioxT25:C1FullSpectrum
(Hybrid)
25mg/mlTHC|1mg/mlCBD
Coming
CellenT5:C25FullSpectrumOil
(Sativa)
5mg/mlTHC|25mg/mlCBD
£5/ml
NoidecsT10:C15FullSpectrumOil
(Sativa)
10mg/mlTHC|15mg/ml
CBD
£3.50/ml
NoidecsT25:C25FullSpectrumOil
(Sativa)
25mg/mlTHC|25mg/ml
CBD
£5/ml
CellenT20:C0BroadSpectrumOil
(Sativa)
20mg/mlTHC|TraceCBD
£5/ml
CellenT5:C50FullSpectrumOil
(Sativa)
5mg/mlTHC|50mg/ml
CBD
£5/ml
NoidecsT26:C0FullSpectrumOil
(Hybrid)
26mg/mlTHC|TraceCBD
£3.50/ml
CellenT0:C100BroadSpectrumOil
(Sativa)
TraceTHC|100mg/mlCBD
£9.17/ml
Flower & Oils – July 2022 Pricing
a
a
Prices from MedBud , GBPEUR = €1.14
Clinics and Pharmacies participating in
Project Twenty21 and indication of fees
d
d
Drug Science
Other
Glaucoma
Heart disease
Epilepsy
Schizophrenia
Peripheral neuropathy
Spinal cord injury
Cancer
High blood pressure
IBD
Psoriasis
Autism spectrum disorder
PTSD
Insomnia
Arthritis
Chronic pain
Anxiety
Depression
6.2%
1.7%
1.9%
1.9%
2.0%
2.0%
2.2%
2.7%
3.3%
3.7%
4.0%
4.4%
5.3%
5.5%
6.9%
9.9%
17.2%
19.2%
UK National Survey of Conditions/Symptoms
Cannabis usage for medical purposes %
c
Other:
HIV/AIDs, Huntington’s disease,
Parkinson’s disease,
Vascular disease, MS
Immunosuppression
c
Source: Scale of Illegal Cannabis Use for Medicinal Intent in the UK
Taken from a YouGov survey of about 10,000 UK adults (4916 participants
had medical conditions of whom 281 reported use of cannabis)